ATE392216T1 - Mycobakterieller impfstoff - Google Patents

Mycobakterieller impfstoff

Info

Publication number: ATE392216T1
Authority: AT; Austria
Prior art keywords: compositions; methods; mycobacterial vaccine; subject; mycobacterial
Prior art date: 2001-11-14

Application number

AT02802568T

Other languages

English (en)

Inventor

Craig Wright

Joan Brisker

Mark Chambers

Original Assignee

Novavax Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-14

Filing date

2002-11-13

Publication date

2008-05-15

2002-11-13 Application filed by Novavax Inc filed Critical Novavax Inc

2008-05-15 Application granted granted Critical

2008-05-15 Publication of ATE392216T1 publication Critical patent/ATE392216T1/de

Links

229960005486 vaccine Drugs 0.000 title 1
239000000203 mixture Substances 0.000 abstract 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 2
206010062207 Mycobacterial infection Diseases 0.000 abstract 1
241000186359 Mycobacterium Species 0.000 abstract 1
241000186366 Mycobacterium bovis Species 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
230000036039 immunity Effects 0.000 abstract 1
208000027531 mycobacterial infectious disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

AT02802568T 2001-11-14 2002-11-13 Mycobakterieller impfstoff ATE392216T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US33591701P	2001-11-14	2001-11-14

Publications (1)

Publication Number	Publication Date
ATE392216T1 true ATE392216T1 (de)	2008-05-15

Family

ID=23313769

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02802568T ATE392216T1 (de)	2001-11-14	2002-11-13	Mycobakterieller impfstoff

Country Status (10)

Country	Link
US (1)	US7393541B2 (de)
EP (1)	EP1467771B1 (de)
JP (1)	JP2005538923A (de)
KR (1)	KR20040081423A (de)
CN (1)	CN1612753A (de)
AT (1)	ATE392216T1 (de)
AU (1)	AU2002364952B2 (de)
CA (1)	CA2467271A1 (de)
DE (1)	DE60226175T2 (de)
WO (1)	WO2003051288A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60226175T2 (de) *	2001-11-14	2009-07-09	Novavax, Inc.	Mycobakterieller impfstoff
WO2005056752A2 (en)	2003-10-24	2005-06-23	Gencia Corporation	Methods and compositions for delivering polynucleotides
US8062891B2 (en)	2003-10-24	2011-11-22	Gencia Corporation	Nonviral vectors for delivering polynucleotides to plants
US8133733B2 (en)	2003-10-24	2012-03-13	Gencia Corporation	Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en)	2003-10-24	2009-05-14	Gencia Corporation	Transducible polypeptides for modifying metabolism
US8507277B2 (en)	2003-10-24	2013-08-13	Gencia Corporation	Nonviral vectors for delivering polynucleotides
CU23460A1 (es) *	2004-03-18	2009-12-01	Inst Finlay Ct De Investigacio	Composiciones vacunales obtenidas a partir de streptomyces
WO2006071659A1 (en) *	2004-12-29	2006-07-06	Trustees Of Boston University	Delivery of h2 antagonists
CN100999550B (zh) *	2006-01-10	2010-10-06	中国人民解放军第三○九医院	结核分枝杆菌融合蛋白及其应用
EP2111232A4 (de) *	2006-07-06	2010-09-08	Rajesh Shah	Neue medizinische formulierung zur auslösung einer immunantwort bei patienten mit chronischen und wiederkehrenden infektionen
DK2144626T3 (en) *	2007-04-12	2015-02-09	Mico Bio Inc	Tuberculosis vaccine and method of using same
JP5835741B2 (ja) *	2010-02-26	2015-12-24	国立大学法人長崎大学	抗原または薬物送達複合体
US20130195800A1 (en)	2010-03-23	2013-08-01	Intrexon Corporation	Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
DK2694101T3 (en)	2011-04-06	2017-01-09	Biovaxim Ltd	Pharmaceutical compositions for the prevention and / or treatment of HIV disease in humans
WO2012137072A1 (en)	2011-04-06	2012-10-11	Biovaxim Limited	Therapeutic vaccine compositions inducing tolerance to hiv for treating hiv infections in humans
WO2014145923A2 (en)	2013-03-15	2014-09-18	The Trustees Of The Univeristy Of Pennsylvania	Synthetic immunogens for prophylaxis or treatment of tuberculosis
KR101696514B1 (ko) *	2014-08-18	2017-01-24	서울대학교산학협력단	신규한 온도 민감성 마이코박테리아 균주 및 이를 포함하는 마이코박테리아 감염증에 대한 백신 조성물
US11077179B2 (en) *	2017-08-10	2021-08-03	Epicgenetics, Inc.	Method for treating fibromyalgia and chronic fatigue syndrome
WO2020115161A1 (en)	2018-12-04	2020-06-11	Sabiotec Spin-Off Sl	Immunostimulant for use against pathogens
CN115154595B (zh) *	2021-12-22	2026-02-17	国药集团动物保健股份有限公司	纳米结构脂质载体佐剂的制备方法以及兽用疫苗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5474848A (en) *	1987-03-13	1995-12-12	Micro-Pak, Inc.	Paucilamellar lipid vesicles
US6387373B1 (en) *	1993-01-15	2002-05-14	Novavax, Inc.	Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
CA2183435C (en) *	1994-02-24	2008-05-13	Craig D. Wright	Vaccines containing paucilamellar lipid vesicles as immunological adjuvants
US6290987B1 (en) *	1998-09-27	2001-09-18	Generex Pharmaceuticals, Inc.	Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
SE9900495D0 (sv) *	1999-02-12	1999-02-12	Pharmatrix Ab	Vaccine composition
EP1265840A2 (de) *	2000-03-17	2002-12-18	Corixa Corporation	Neue amphipatische aldehyde und ihre verwendung als adjuvanten und immunoeffektoren
GB0109297D0 (en) *	2001-04-12	2001-05-30	Glaxosmithkline Biolog Sa	Vaccine
DE60226175T2 (de) *	2001-11-14	2009-07-09	Novavax, Inc.	Mycobakterieller impfstoff
US20050175630A1 (en) *	2003-12-23	2005-08-11	Eyal Raz	Immunogenic compositions and methods of use thereof

2002
- 2002-11-13 DE DE60226175T patent/DE60226175T2/de not_active Expired - Lifetime
- 2002-11-13 AU AU2002364952A patent/AU2002364952B2/en not_active Ceased
- 2002-11-13 WO PCT/US2002/036336 patent/WO2003051288A2/en not_active Ceased
- 2002-11-13 JP JP2003552221A patent/JP2005538923A/ja not_active Withdrawn
- 2002-11-13 EP EP02802568A patent/EP1467771B1/de not_active Expired - Lifetime
- 2002-11-13 KR KR10-2004-7007377A patent/KR20040081423A/ko not_active Ceased
- 2002-11-13 CN CNA02826665XA patent/CN1612753A/zh active Pending
- 2002-11-13 CA CA002467271A patent/CA2467271A1/en not_active Abandoned
- 2002-11-13 AT AT02802568T patent/ATE392216T1/de not_active IP Right Cessation
2004
- 2004-05-13 US US10/846,939 patent/US7393541B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7393541B2 (en)	2008-07-01
CA2467271A1 (en)	2003-06-26
WO2003051288A3 (en)	2003-11-27
DE60226175T2 (de)	2009-07-09
AU2002364952B2 (en)	2008-04-10
JP2005538923A (ja)	2005-12-22
KR20040081423A (ko)	2004-09-21
AU2002364952A1 (en)	2003-06-30
WO2003051288A2 (en)	2003-06-26
EP1467771A2 (de)	2004-10-20
DE60226175D1 (de)	2008-05-29
EP1467771B1 (de)	2008-04-16
CN1612753A (zh)	2005-05-04
EP1467771A4 (de)	2006-01-11
US20050118201A1 (en)	2005-06-02

Legal Events

Date	Code	Title	Description
2008-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60226175D1 (de)	2008-05-29	Mycobakterieller impfstoff
ATE426412T1 (de)	2009-04-15	Adjuvante influenza-vakzine
DK1401489T4 (da)	2013-07-01	Solubilisering af kapselpolysaccharid
DK1104306T3 (da)	2006-05-22	Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
WO2003080114A3 (en)	2003-11-06	Imidazoquinoline adjuvants for vaccines
CY1106669T1 (el)	2012-05-23	Βελτιωμενο i mycoplasma hy opneumoniae/ i εμβολιο βακτηρινης
CY1115842T1 (el)	2017-01-25	Συμπληρωμενο ομv εμβολιο κατα μηνιγγιtiδοκοκκου
PT865297E (pt)	2003-03-31	Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
NO20063254L (no)	2006-07-13	Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist
CY1108526T1 (el)	2014-04-09	Εμβολια εναντι καρκινων
WO2002010343A3 (en)	2002-10-10	Temperature-sensitive live vaccine for mycoplasma hyopneumoniae
NO20075727L (no)	2008-02-15	Vaksineblanding omfattende B-subenhet av et E.coli varmetoksin og et antigen og en adjuvans
EP1395283A4 (de)	2005-06-08	Heterologer schutz, induziert durch immunisierung mit der invaplex-vakzine
AU2001284354A1 (en)	2002-02-13	Immunological adjuvant compounds, compositions, and methods of use thereof
WO2000050073A3 (en)	2001-02-22	Caulobacter lps immunoadjuvant
SG147465A1 (en)	2008-11-28	Vaccine
EP1667634A4 (de)	2008-03-05	Anthrax-vakzine
WO2006095176A3 (en)	2007-04-05	Vaccine formulation
ATE353226T1 (de)	2007-02-15	Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
UA67251A (en)	2004-06-15	Strain paramixovirus-3 bovis "zksm" for the preparation of vaccines and diagnosticums